Brookfield Corp’s CareDx CDNA Stock Holding History

Brookfield Corp’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,456	Closed	-$657K	–	644
2021 Q4	$657K	Buy	+14,456	New	+$755K	﹤0.01%	514
2020 Q4	–	Sell	-9,597	Closed	-$364K	–	446
2020 Q3	$364K	Buy	+9,597	New	+$324K	﹤0.01%	360

Other funds holding CDNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Brookfield Corp's CDNA Position: Q1 2022 in Review

Brookfield Corp sold out of CareDx (CDNA) in Q1 2022, closing a stake of 14,456 shares — an estimated $657K sold.

Brookfield Corp first reported a position in CDNA in Q3 2020 and held it in 2 quarters. The position peaked at $657K in Q4 2021. 213 funds tracked by Wall St. Rank hold CDNA as of Q1 2022.

Brookfield Corp reported no remaining CareDx position as of Q1 2022 after selling out during the quarter.
Brookfield Corp sold 14,456 CareDx shares in Q1 2022, an estimated $657K.
Brookfield Corp first reported a position in CareDx in Q3 2020 and held it in 2 quarters.
Brookfield Corp's CareDx position peaked at $657K in Q4 2021.
213 funds tracked by Wall St. Rank held CareDx as of Q1 2022.

Based on Brookfield Corp's 13F filing for Q1 2022, filed 16 May 2022.